The lawsuit claims that CMS's plan to include the drug, Xphozah, along with all other oral-only phosphate lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD) will "significantly and negatively impact patient choice of and timely access to important medications."
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Ij29vks
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment